One unasked intake question stands between you and MRONJ

For most people taking a bisphosphonate for osteoporosis, the chance of developing osteonecrosis of the jaw after a dental procedure is low. That concession matters, because the wrong way to read this article is as a reason to refuse a needed extraction or to stop a bone-protecting drug out of fear. The absolute risk at osteoporosis doses is small [1]. Plenty of people on these medications have teeth out and implants placed without incident.

Now the pivot, and it is a sharp one. The reason that low risk stays low is that someone asked. The protection against medication-related osteonecrosis of the jaw, MRONJ, is almost entirely front-loaded into a single act: identifying that the patient is on an antiresorptive drug before anything invasive happens. Establish that one fact and the whole apparatus of prevention switches on. Miss it, and the patient walks into an extraction socket with an elevated risk that nobody is managing because nobody knows it exists. In a series called What the Intake Form Skips, this is the starkest entry, because the protective intervention is not a blood test or a machine. It is one question, and it is free.

What MRONJ is, in concrete terms

The American Association of Oral and Maxillofacial Surgeons defines MRONJ as exposed bone, or bone that can be probed through an intraoral or extraoral fistula in the jaw region, that has persisted for more than eight weeks, in a patient treated with an antiresorptive or antiangiogenic medication, with no history of radiation to the jaws and no obvious metastatic disease in the bone [1]. Strip out the qualifiers and it means this: a patch of jawbone dies and refuses to heal, often after a tooth comes out or an implant goes in, and stays open and dead for months.

It is not a transient soreness. Exposed necrotic bone can persist, become infected, cause pain, and progress. Earlier stages can be managed and can improve, but advanced disease is genuinely difficult to resolve, and management is often long and incomplete [1][2]. That asymmetry is the entire point of this article. On one side, a question that takes ten seconds. On the other, a lesion that can resist treatment for a year or more. There are not many places in dentistry where the prevention is that cheap and the failure mode is that hard to undo.

The drugs, and the patient who is carrying one without thinking about it

The medications that drive MRONJ are antiresorptives and, less commonly, antiangiogenics. The two names to know are bisphosphonates and denosumab [1].

Bisphosphonates include oral drugs such as alendronate and risedronate, taken weekly or monthly for osteoporosis, and intravenous drugs such as zoledronate and pamidronate, used at higher doses in cancer care [3]. Denosumab is a monoclonal antibody given by injection, also used for osteoporosis and for bone metastases [4]. The crucial behavioural fact is that the patient often does not connect these drugs to their mouth at all. A once-weekly osteoporosis tablet, taken for years, does not feel like a surgical risk factor to the person taking it. An older adult filling in a rushed intake form abroad, in a second language, may simply not list it, or may not be asked in a way that prompts recall.

That is why the question has to be the clinic’s job, asked deliberately and specifically. “Do you take any medication for your bones, including osteoporosis tablets or injections” catches the patient that “any medical conditions” misses. The home dentist usually has the prescribing record or a GP a phone call away. The overseas one-trip intake usually has neither, which makes the explicit question even more essential, and its absence even more dangerous.

The mechanism: why bone that cannot remodel cannot heal a socket

To see why these drugs do this, you have to understand that healthy bone is not static. It is constantly being broken down and rebuilt in a balanced cycle. Cells called osteoclasts resorb old bone; cells called osteoblasts lay down new bone. This turnover is how bone repairs micro-damage and, critically, how an extraction socket heals: the dead and damaged bone at the socket margins must be resorbed and replaced with new bone.

Antiresorptive drugs work by suppressing osteoclasts. For osteoporosis that is the therapeutic goal, slowing the loss of bone and reducing fracture risk [3][4]. But the same suppression that protects the skeleton also blunts the jaw’s ability to remodel and heal after trauma. The jaws are especially exposed because the mouth is a contaminated environment with a thin mucosal covering over bone, subjected to constant mechanical and microbial insult. When you extract a tooth or place an implant, you create a wound in exactly the tissue whose repair machinery these drugs have turned down.

  Antiresorptive drug (bisphosphonate / denosumab)
            |
            v
  Osteoclast activity suppressed
            |
            v
  Bone turnover and remodelling slowed
            |
  Tooth extraction or implant surgery
  creates a bony wound that must remodel to heal
            |
            v
  Wound cannot resorb damaged bone and lay down new bone
            |
   +--------+-------------------+
   v                            v
 Bone fails to revascularise   Oral bacteria colonise
 and re-cover with tissue      exposed bone
            \                  /
             \                /
              v              v
        Exposed, non-healing necrotic bone
              = MRONJ (>8 weeks)

Concede the nuance the guidance itself insists on. The risk is dose- and duration-dependent and is far higher in the cancer setting than in osteoporosis care; intravenous administration and tooth extraction are major risk amplifiers, and most osteoporosis patients on oral drugs never develop MRONJ [1]. The mechanism explains the risk; it does not make the risk universal. But it does make one thing unavoidable: you cannot manage a risk created by a drug you do not know the patient is taking.

Why “one question” really is the whole defence

It is worth being precise about what knowing changes, because the value of the question is that it unlocks every downstream protection at once. Once a clinician knows an antiresorptive is on board, the AAOMS framework supports a cascade of measured responses [1]:

The clinician can weigh whether the planned procedure is necessary at all, or whether a less invasive alternative achieves the goal. For a tooth that might be saved, the calculus shifts toward saving it; this is one of the places where the endodontic option of keeping a natural tooth, rather than extracting and implanting, becomes more than a preference. The clinician can coordinate with the prescribing physician about the drug, its dose, its duration, and whether any modification is appropriate, a decision that belongs to the prescriber, not the dentist. The procedure can be timed and performed with techniques that respect the raised risk. And the patient can be consented honestly, with the actual risk on the table rather than discovered afterward.

Every one of those protections has a single prerequisite: the question was asked and answered. Skip it, and the whole cascade never starts. The extraction proceeds as though the patient were standard risk, because to everyone in the room, that is exactly what the patient appears to be. The damage, if it comes, declares itself weeks later, by which time the patient has flown home and the eight-week clock that defines MRONJ has barely begun to run.

The overseas gap, structurally

This is the cleanest illustration in the whole What the Intake Form Skips series of how the omission is structural rather than careless. The drug question costs nothing, adds no lab fee, and takes seconds. So why does it go missing abroad more than at home?

Partly because the at-risk patient is invisible without being asked specifically, and a generic intake form rarely asks specifically. Partly because there is no shared medical record, the same void that produces the drug-interaction blind spot for prescribed antibiotics; the clinic cannot pull a medication list it does not have. And partly because a thorough drug history is the kind of friction a fixed-itinerary booking is built to minimise, the same incentive that drives package-deal overtreatment. At home, the dentist sits inside a continuous record and a referral network that make the antiresorptive history almost automatic. Strip those supports away and the protection collapses to a question the form has to be designed to ask, and often is not. This is one of the clearest cases where the dental tourism trust gap is not about skill at all, but about the information the system does and does not carry.

What a patient should verify

This is a decision framework, not treatment advice, and nothing here should prompt anyone to stop a bone-protecting medication. Any change to an antiresorptive drug is a decision for the prescribing doctor. But three concrete items separate a clinic that takes MRONJ seriously from one that has never thought about it.

1. State your full medication history, including bone drugs, in writing and unprompted. Do not wait to be asked. List every osteoporosis tablet and injection, current and past, with as accurate a duration as you can manage. Bring it on paper. If you have ever taken a bisphosphonate or denosumab, say so explicitly, because the form may not ask in a way that triggers your memory. You are closing the gap the intake form leaves open.

2. Ask whether the clinic screens specifically for antiresorptive drugs before extractions and implants. A clinic that has a real MRONJ protocol will be able to describe what it asks and what it does with the answer. A clinic that meets the question with a blank look has told you something important. The right answer references the drug class by name, not just “any medications.”

3. Ask what the clinic would do if you were on one of these drugs. The acceptable answers involve consideration of less invasive alternatives, coordination with your prescriber, honest consent about raised risk, and a willingness to delay or reconsider. An answer that amounts to “we proceed as normal” is the answer that should worry you most, because it means the one question that could have protected you would have changed nothing anyway.

The one question that changes the plan

Reduced to its core, MRONJ prevention is a single sentence: do you take, or have you taken, any medication for your bones. That sentence is the difference between a managed risk and an unmanaged one, between an honest consent conversation and a complication discovered too late, between a tooth considered for saving and a socket left to heal in bone that cannot heal it.

The home pathway asks it almost reflexively because the dentist is inside a system that carries the medication history forward. The overseas one-trip pathway often does not, not out of recklessness but because the patient is invisible without the specific question, the shared record that would surface the drug does not exist, and the question is friction on a fixed schedule. The fix sits with the patient in this case more than in any other entry in the series: you can volunteer the answer before anyone asks. For how we weigh evidence and source these claims, and for the rest of the systemic risks an intake form skips, from undiagnosed diabetes to uncontrolled hypertension in a long sedation session, see our methodology and the companion pieces in this series.

The second wave of this series extends the same argument into finer cells: prior head-and-neck radiation and osteoradionecrosis, anticoagulants, a fresh extraction, and a dry cabin, and immunosuppression and the early implant-healing window.